Bio-Connect
WB analysis of various samples using GTX85102 B-Raf antibody. Dilution : 0.5microg/mL Loading : 15microg of lysates per lane
WB analysis of various samples using GTX85102 B-Raf antibody. Dilution : 0.5microg/mL Loading : 15microg of lysates per lane
WB analysis of various samples using GTX85102 B-Raf antibody. Dilution : 0.5microg/mL Loading : 15microg of lysates per lane

B-Raf antibody

GTX85102
GeneTex
TargetBRAF
Product group Antibodies
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    GeneTex
  • Product Name
    B-Raf antibody
  • Delivery Days Customer
    9
  • Application Supplier Note
    WB: 0.5-2 microg/mL. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
  • Concentration
    1 mg/ml
  • Formulation
    Liquid
  • Gene ID673
  • Target name
    BRAF
  • Target description
    B-Raf proto-oncogene, serine/threonine kinase
  • Target synonyms
    94 kDa B-raf protein; B-raf; B-Raf proto-oncogene serine/threonine-protein kinase (p94); B-Raf serine/threonine-protein; BRAF1; B-RAF1; murine sarcoma viral (v-raf) oncogene homolog B1; NS7; proto-oncogene B-Raf; RAFB1; serine/threonine-protein kinase B-raf; v-raf murine sarcoma viral oncogene homolog B; v-raf murine sarcoma viral oncogene homolog B1
  • Protein IDP15056
  • Protein Name
    Serine/threonine-protein kinase B-raf
  • Scientific Description
    B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. The Ras/Raf/MEK/ERK and Ras/PI3K/PTEN/Akt pathways interact with each other to regulate growth and in some cases tumorigenesis. Mutations in B-raf have been associated with several cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung, leading to speculation on the possibility of B-raf as a therapeutic target for treating cancers. Mutations in this gene have also been associated with cardiofaciocutaneous syndrome (CFCS), a disease characterized by heart defects, mental retardation and a distinctive facial appearance.
  • Storage Instruction
    -20°C or -80°C,2°C to 8°C
  • UNSPSC
    12352203